A heparin-bonded covered stent may hold some advantages over bare-metal stents (BMS) for treatment of long diffuse superficial femoropopliteal artery (SFA) disease, according to data published online ...
Please provide your email address to receive an email when new articles are posted on . Among patients who had endovascular revascularization of the superficial femoral artery, stent thrombosis ...
New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery MINNEAPOLIS –– ...
BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical announced that a new 5 mm diameter version of Zilver ® PTX ® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths ...
MILPITAS, Calif.--(BUSINESS WIRE)--PQ Bypass, Inc., a clinical-stage medical device company, today announced it has received full approval of its investigational device exemption (IDE) trial of the ...
Please provide your email address to receive an email when new articles are posted on . The use of a drug-coated balloon after stent graft treatment of superficial femoral artery occlusive disease ...
The U.S. FDA has given Pq Bypass Inc. the greenlight to conduct a pivotal trial aimed at assessing its Torus stent graft in the treatment of peripheral artery disease (PAD) in the superficial femoral ...
Four-year data from the Zilver® PTX® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical presented today at the 2013 Vascular Interventional Advances ...
Cook Medical announced that a new 5 mm diameter version of Zilver ® PTX ® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results